The study was led by Dr. Kimberly Sullivan of Boston University and. Dr. Mohammed Abou-Donia of Duke University.
It was funded by the treatment-focused Gulf War Illness Research Program (GWIRP), part of the Congressionally Directed Medical Research Program (CDMRP) funded by Congress under the U.S. Department of Defense health program.
It also incorporated data from a GWIRP-funded treatment study by Dr. Lisa Conboy of acupuncture, which showed good success in helping to reduce pain related to Gulf War Illness.
Sullivan also leads the Gulf War Illness Consortium (GWIC) at Boston University, a very large GWIRP-funded project that is currently recruiting up to 300 healthy and ill veterans of the 1991 Gulf War (Operation Desert Storm) in Boston, Houston, and Miami. Participation in the study will help as many as 250,000 fellow Gulf War veterans who remain ill, and may also help other veterans who have suffered similar toxic exposures.
Abou-Donia performed some of the earliest Gulf War Illness research, funded by Ross Perot, that showed that damage in laboratory animals by Gulf War chemical agents mirrored Gulf War Illness health effects.
Validation efforts of the biomarkers identified in the study are already in progress.
-Anthony Hardie, 91outcomes.com
SOURCE: PubMed, ePub ahead of publication, Mar. 9, 2017
Neurotoxicol Teratol. 2017 Mar 9. pii: S0892-0362(17)30050-8. doi: 10.1016/j.ntt.2017.03.002. [Epub ahead of print]
Screening for novel central nervous system biomarkers in veterans with Gulf War Illness.
Abou-Donia MB1, Conboy LA2, Kokkotou E3, Jacobson E4, Elmasry EM5, Elkafrawy P6, Neely M7, Bass CR8, Sullivan K8.
Copyright © 2017. Published by Elsevier Inc.
Autoantibodies; Brain injury; Cytoskeletal proteins; Gulf War Illness; Serum biomarkers